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Available online 3 February 2016Receptor-mediated antibody internalization is a key mechanism underlying several anti-cancer antibody
therapeutics. Delivering highly toxic drugs to cancer cells, as in the case of antibody drug conjugates (ADCs),
efﬁcient removal of surface receptors from cancer cells and changing the pharmacokinetics proﬁle of the anti-
body drugs are some of key ways that internalization impacts the therapeutic efﬁcacy of the antibodies. Over
the years, several techniques have been used to study antibody internalization including radiolabels, ﬂuorescent
microscopy, ﬂow cytometry and cellular toxicity assays. While these methods allow analysis of internalization,
they have limitations including a multistep process and limited throughput and are generally endpoint assays.
Here, we present a new homogeneous method that enables time and concentration dependent measurements
of antibody internalization. The method uses a new hydrophilic and bright pH sensor dye (pHAb dye), which
is not ﬂuorescent at neutral pH but becomes highly ﬂuorescent at acidic pH. For receptor mediated antibody
internalization studies, antibodies against receptors are conjugated with the pHAb dye and incubated with the
cells expressing the receptors. Upon binding to the receptor, the dyes conjugated to the antibody are not
ﬂuorescent because of the neutral pH of the media, but upon internalization and trafﬁcking into endosomal
and lysosomal vesicles the pH drops and dyes become ﬂuorescent. The enabling attributes of the pHAb dyes
are the hydrophilic nature to minimize antibody aggregation and bright ﬂuorescence at acidic pH which allows
development of simple plate based assays using aﬂuorescent reader. Using two different therapeutic antibodies –
Trastuzumab (anti-HER2) and Cetuximab (anti-EGFR) –we show labeling with pHAb dye using amine and thiol
chemistries and impact of chemistry and dye to antibody ration on internalization. We ﬁnally present two new
approaches using the pHAbdye,whichwill be beneﬁcial for screening a large number of antibody samples during
early monoclonal development phase.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Receptor-mediated antibody internalization plays an important role
in efﬁcacy and dosage of therapeutic antibodies. For example, efﬁcacy of
antibody drug conjugates (ADCs) (Casi and Neri, 2012; Drachman and
Senter, 2013; Panowksi et al., 2014; Ritchie et al., 2013) is to a large
extent driven by the efﬁciency of antibody internalization followed by
trafﬁcking into the lysosomal compartment and release of the toxic
drugmolecule leading to cell death (Flygare et al., 2013). More recently,
it has been reported that in the case of epidermal growth factor receptor
(EGFR) induced cancers, a superior response is observed if the EGFR is
efﬁciently removed from the surface by inducing receptor internaliza-
tion and degradation (Pedersen et al., 2010; Ben-Kasus et al., 2009;. This is an open access article underFriedman et al., 2005; Kontermann, 2012). In this case, improved efﬁca-
cy of the treatment was observed when a mixture of antibodies
targeting different epitopes of EGFR led to enhanced receptor internali-
zation. This approach is different from the current approach of targeting
EGFR with a single antibody like Cetuximab or Panitumumab, which
works mainly by inhibiting EGF binding and receptor dimerization
and inducing ADCC (Antibody Dependent Cell Cytotoxicity). While
receptor-mediated antibody internalization improves the efﬁcacy of
antibody therapeutics, it can also have an opposite effect because inter-
nalization can lead to rapid clearance of the drug in vivo and hencemay
require high antibody dosage or frequent dosing (Chaparro-Riggers
et al., 2012; Amano et al., 2010; Lammerts van Bueren et al., 2006).
In spite of increasing awareness that internalization is a critical
antibody attribute, antibodies continue to be screened only for afﬁnity
binding using Enzyme Linked Immunosorbent Assay (ELISA) during
early monoclonal development phase. This approach may not be
optimal since there is some evidence that high afﬁnity may not alwaysthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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need for high throughput methods to screen antibodies speciﬁcally for
internalization properties.
Several methods have been used to study receptor-mediated anti-
body internalization (Casalini et al., 1993; Isa et al., 2014; Liao-Chan
et al., 2015; Hazin et al., 2015). Confocal imaging using ﬂuorescence
labeled antibodies is perhaps the most frequently employed and has
the ability to localize antibodies upon internalization into speciﬁc sub-
cellular compartments like the endosome and lysosome. The imaging
based methods are low throughput and offer mostly qualitative data.
For quantitative data, antibodies labeled with radioisotopes or ﬂuores-
cent molecules are incubated with the cells and allowed to internalize.
After removing membrane associated antibodies using a low pH
(pH ~ 2.5) wash, the internalized antibodies are detected by measuring
radioactivity or ﬂuorescence intensity of the cells. The acid wash
methods are endpoint assays, have deleterious effects on the cells and
have low signal over background ratios if the washing is not efﬁcient.
A variation of this approach uses a secondary antibody targeted against
the ﬂuorescent tag to quench the signal on the cell membrane (Liao-
Chan et al., 2015) and have the advantage that it avoids the cell apopto-
sis resulting from low pH wash. The method is an endpoint assay with
multiple incubation and washing steps. Homogeneous internalization
assays have been reported including one using a dual labeled antibody
(Gong and Urlacher, 2015) and also using antibodies labeled with pH
sensitive dyes (Berguig et al., 2012; Ogawa et al., 2010; Gostring et al.,
2010; Nordberg et al., 2008). The pH sensitive dyes are not ﬂuorescent
at neutral pH but become ﬂuorescent when they internalize and trafﬁc
into low pH vesicles like endosome and lysosome. However, these
dyes have not been routinely used for antibody screening ormonitoring
kinetics of internalization probably due to a relatively small increase in
ﬂuorescence on pH change (Isa et al., 2014; Liao-Chan et al., 2015). All of
themethods described above are also limited in their throughput or lack
sufﬁcient sensitivity to be used as a screening tool (see note at the endof
the Conclusion section).
In this paper, we describe a method to study antibody internaliza-
tion, which is sensitive, speciﬁc and can be used in a simple 96-well
plate based format for screening purposes. The method relies on a
new pH sensor dye (pHAb dye) comprising a rhodamine-class core
structure and two substituted piperazine groups (Fig. 1). The dye
shows very low ﬂuorescence at pH ≥ 7.5 and a dramatic increase in
the ﬂuorescence at pH b 6. The dye has excitation and emission
maximum of 532 nm and 560 nm, is photostable in solution and
displays no loss of signal with multiple cycles of acid, base titration.Fig. 1.A)Amine reactive pH sensor (pHAb) dyewith succinimidyl ester reactive group for bindin
reactive group for binding to free thiol available on reduced cysteines.We have recently reported the use of the dye to detect ligand mediated
receptor internalization (Robers et al., 2015). For antibody internaliza-
tion studies, two reactive versions of the dye – an amine and a thiol
reactive form – were made. The amine reactive dye has a succinimidyl
ester group for binding to a lysine amino acid and the thiol reactive
version has a maleimide reactive group for binding to reduced cysteine
in the antibody hinge region. To make the dyes compatible for protein
conjugation, they were also sulfonated, which makes them hydrophilic
and less prone to precipitating the antibody. Antibodies labeled with
pHAb dyes upon binding to receptors on the cell membrane will not
be ﬂuorescent due to the neutral pH of the media. However, upon
receptor-mediated internalization, antibodies will trafﬁc into early
endosomes and lysosomes where the pH is acidic and the dye will ﬂuo-
resce allowing visualization of the dye labeled antibodies. A signiﬁcant
increase in ﬂuorescence of pHAb dyes in an acidic environment
combined with the hydrophilic nature of the dye makes them uniquely
suitable for monitoring antibody internalization.
To demonstrate the broad utility of the pHAb dye for receptor-
mediated antibody internalization, we successfully used it to develop
an internalization assay for two therapeutic antibodies, Trastuzumab
and Cetuximab, which bind to HER2 and EGFR respectively. Both the
antibodies, which are known to internalize (Panowksi et al., 2014;
Pedersen et al., 2010), were labeled with pHAb dyes using amine or
thiol chemistry and used for time and concentration dependent
internalization studies and read on a 96-well ﬂuorescent plate reader.
The assay is homogeneous and internalization can be monitored in
real time without removing excess antibody. To further simplify the
assay to make it suitable for screening applications we show that:
(a) antibodies can be labeled with pHAb dyes and used without remov-
ing excess dye and (b) secondary antibodies labeled with pHAb can be
used instead of labeling primary antibodies.
2. Material and methods
2.1. pHAb dye chemistry
The structure and synthesis of the amine reactive succinimidyl ester
derivative (Fig. 1A) were reported recently (Robers et al., 2015). The
thiol reactive pHAb maleimide (Fig. 1B) was synthesized as described.
N,N-diisopropylethylamine (0.48 ml, 2.77 mmol) was added to a
suspension of 3′,6′-Bis(4-(4-sulfobutyl)piperazin-1yl) rhodamine (5′,6′)
carboxylic acid (311.0 mg, 0.4 mmol), N-(2-Aminoethyl)maleimide,
triﬂuoroacetate salt (123.3 mg, 0.49 mmol), and HATU (182.5 mg,g at the primary amine present on lysines. B) Thiol reactive pH sensor dyewithmaleimide
Table 1
Dye to antibody ratio (DAR) of Trastuzumab and Cetuximab labeled with pHAb dye using
amine and thiol chemistries. 5, 10, and 20M excess of dye relative to antibodywas used to
get a range of DAR.
Molar excess of pHAb
dye relative to antibody
Trastuzumab
Thiol-pHAb
Trastuzumab
Amine-pHAb
Cetuximab
Thiol-pHAb
Cetuximab
Amine-pHAb
5× 1.9 3.5 1.7 2.8
10× 3.4 5.8 2.8 4.7
20× 3.9 9.4 3.9 8.5
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stirred for 90 min and was quenched by the addition of excess neat
triﬂuoroacetic acid. The resulting mixture was diluted with 1%
triﬂuoroacetic acid inwater and subjected to preparative RP-HPLC puriﬁ-
cation to give the title compound (132 mg, 36.7%). MS (ESI) m/z
calculated for C43H50N6O12S2 (M+ H+) 907.3, found 907.3.
2.2. pHAb conjugation to antibody
Antibodies were conjugated with pHAb dye either using amine
chemistry or thiol chemistry according to a manufacturer (Promega)
recommended protocol. Brieﬂy, for conjugating antibody with pHAb
dye at lysine amino acids, antibody is reacted with an excess of amine
reactive pHAb dye (5–20 molar excess) for 1 h. Free dye was subse-
quently removed using a Zeba desalting column (Thermo-Scientiﬁc)
and the concentration of dye-labeled antibody and dye to antibody
ratio (DAR) was calculated as recommended by the manufacturer. For
labeling antibody with thiol reactive pHAb dye, disulﬁde bonds present
in the antibody hinge regionwere ﬁrst reduced to free thiols by incubat-
ing for 1 h with 2.5 mM DTT. Excess DTT is removed using a Zeba
desalting column followed by a 1 h reactionwith excess of thiol reactive
pHAb dye (5–20 M excess). Excess dye was removed as before and the
concentration of pHAb labeled antibody as well as DAR was calculated
according to the manufacturer's protocol (Promega).
2.3. Cell based ELISA
SKBR3 cells overexpressingHER2 andA431 cells overexpressing EGFR
were plated at 15,000 cells per well in a 96-well polystyrene plate and
grown to conﬂuence by overnight incubation at 37 °C, then ﬁxed using
4% paraformaldehyde. Dilution series of Trastuzumab and Cetuximab la-
beledwith pHAbdyeweremade in PBS containing 10mg/ml BSA (PBSB).
50 μl samples were added to the respective plates in triplicate and incu-
bated for 1 h. After washing with PBS containing 0.05% Tween 20
(PBST), plates were incubated for 1 h with anti-Human-IgG (H + L)-
HRP (horseradish peroxidase) conjugate (Promega) diluted 1:5000-fold
in PBSB. After washing with PBST, TMB (3,3´, 5,5´-tetramethylbenzidine)
(Promega) was used as the HRP substrate. The colorimetric reaction was
stopped by adding 1N HCl and plates were read at 450 nm. ELISA for
anti-EGFR mouse antibodies was performed using A431 cells as above
except that anti-mouse-IgG-HRP conjugate (Novex) was used at 1:5000
dilution.
2.4. Confocal microscopy for antibody internalization
HER2 positive SKBR3 cells were used to study internalization of
pHAb conjugated Trastuzumab. MCF7 cells with no HER2 on their cell
membrane were used as a negative control. SKBR3 cells were grown
in McCoy's media with 10% fetal bovine serum and MCF7 cells were
grown in Eagle's minimal essential media (MEM)with 10% fetal bovine
serumand 0.01mg/ml human recombinant insulin. Cells were plated at
40 K per well in a Lab Tek II chambered #1.5 German coverglass system
(Nunc) overnight. Media was changed to OptiMEM/4% fetal bovine
serum and cells were treated with 3 nM Trastuzumab-pHAb. Images
were captured on a Nikon C2si confocal microscope (Ex/Em: 561/
580LP nm) every hour for 16 h. The 561 nm diode laser was set at
10%, PMT = 130 V and confocal aperture was 40 μM. To visualize
antibody–pHAb receptor binding, cells were treated with 3.0 nM
Trastuzumab-pHAb for 1 h at 4 °C. Media was removed, washed and
200 μl of OptiMEM/FBS was added. Buffer pH was adjusted by adding
50 μl of 0.1 M Citrate buffer, pH 5.0 or 0.1 M phosphate buffer, pH 8.0.
2.5. Plate based internalization assay
Three different cell lines were used throughout these experiments:
(1) SKBR3 cells overexpressing HER2, for internalization of pHAblabeled Trastuzumab; (2) A431 overexpressing EGFR for internalization
of pHAb labeled Cetuximab; and (3) MCF7 cells without HER2 or EGFR
on their cell membrane as negative control. SKBR3 cells were grown
in McCoy's media with 10% fetal bovine serum, A431 cells were grown
inDMEMwith 10% fetal bovine serumandMCF7 cells using Eagle'smin-
imal essential media (MEM) with 10% fetal bovine serum and 0.01 mg/
ml human recombinant insulin. Cells were grown in T75 cm2 ﬂask over-
night till they reached conﬂuence. Cells were trypsinized and plated in a
96-well black, clear-bottom plate (Costar 3603) or black plate (Thermo
Scientiﬁc #165305) at the density of 20 K per 90 μl per well. A clear bot-
tom plate has the advantage that it allows visualization of antibody in-
ternalization using a confocal microscope or EVOS cell imaging system
(Life Technologies). Plates were incubated for 20–24 h before treatment
with pHAb labeled antibodies.
For internalization, pHAb conjugated antibodies were added to the
cells at the desired concentration and mixed gently for 1–2 min on a
plate mixer and then incubated overnight to allow internalization
(internalization can be detected in a few hours). Plates are read on a
ﬂuorescent plate reader at Ex/Em: 532 nm/560 nm on a Tecan Inﬁnity
M1000 Pro. To achieve higher sensitivity, media is replaced by PBS
before reading the plate. Control wells are treated just with PBS and
ﬂuorescence signal is used as background coming just from the cells
and are subtracted from positive wells.3. Results
3.1. Characterization of pHAb labeled antibodies
Functionality of the labeled antibody is dependent on the chemistry
used for labeling and average number of labels per antibody (Acchione
et al., 2012; Shrestha et al., 2012; Vira et al., 2010). Hence, Trastuzumab
and Cetuximab were labeled with pHAb dyes using both amine and
thiol chemistries, in the presence of 5, 10 and 20 M excess of dye to
get a range of dye to antibody ratios (DARs) (Table 1). DAR of 2.7 to 9
was obtained with amine chemistry whereas for thiol based labeling
method, DAR had a narrower range from 1.7–3.9. DAR of 3.5 and 2.8
for Trastuzumab and Cetuximab respectively was common to both the
chemistries and allowed us to evaluate the impact of dye position on an-
tigen–antibody binding and internalization. pHAb labeled antibody
preparations (n = 12) were evaluated for antigen–antibody binding
activity using ELISA, and for ﬂuorescence response to pH change. For
clarity, we used Trastuzumab-amine-pHAb and Cetuximab-amine-
pHAb to indicate antibodies conjugated using amine chemistry; and
for thiol chemistry, we used Trastuzumab-thiol-pHAb and Cetuximab-
thiol-pHAb.
ELISA results show that themost signiﬁcant impact on antibody–an-
tigen binding happened with Trastuzumab-amine-pHAb (Fig. 2A). A
steady decrease in binding activity of Trastuzumab, as indicated by the
rightward shift of the binding curve, was seen with increase in DAR.
However, when pHAb was conjugated to Trastuzumab using thiol
chemistry (Trastuzumab-thiol-pHAb) the impact of antigen–antibody
binding was minimal (Fig. 2B). This was true even when DARs were
the same for two chemistries indicating that amine chemistry rather
Fig. 2. Impact of labeling chemistry and dye-to-antibody ratio (DAR) on the antigen–antibody binding measured using ELISA. (A) Trastuzumab-amine-pHAb; (B) Trastuzumab-thiol-
pHAb; (C) Cetuximab-amine-pHAb; and (D) Cetuximab-thiol-pHAb. Mean and standard deviation from triplicate readings were plotted.
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pHAb labeling using either amine or thiol chemistry had only a slight
impact on binding to EGFR, even at a high DAR of 8.5 (Fig. 2C and D).
Our results indicate that both the labeling chemistry and antibody
characteristics are important considerations for antibody labeling.
Thiol chemistry places the dyes in the hinge region of the antibodies,
away from the antigen binding site hence minimizing any loss of
antibody–antigen activity. On the other hand, labeling antibodies with
pHAb dye using amine chemistry can place dyes randomly throughout
the antibody surface including near CDR region, which will have signif-
icant inﬂuence on antibody–antigen binding. Our results also point to
the difﬁculty in deciding a priori which chemistry and DAR will work
best for a speciﬁc antibody. Although not seen here, we occasionally
observe some precipitation of labeled antibodies, which is antibody
speciﬁc and may represent an antibody population that is heavily
labeled. In such cases, a brief centrifugation is used to remove aggregated
antibodies and the rest of the sample is very stable.Fig. 3. Change inﬂuorescence as a function of pHmeasured for (A) Trastuzumab-amine-pHAb a
reactive dye (pHAb-ME) are also included. Free dye and dye labeled antibody were diluted in
ﬂuorescent plate reader. Data was normalized to the ﬂuorescence at pH 4.0. Mean and standarIn addition to the impact of pHAb dye on antibody–antigen binding,
the pH response of the pHAb dye after conjugation to antibodies is very
important. Trastuzumab-amine-pHAb and Trastuzumab-thiol-pHAb
alongwith the respective free dyes were diluted into buffers of different
pH and ﬂuorescence was measured (Fig. 3). For Trastuzumab-amine-
pHAb, the increase in ﬂuorescence with decreasing pH was similar to
that of free dye (pHAb-SE) even at a high DAR (Fig. 3A) and had a half
maximal response at around pH 6.5. However, for Trastuzumab-thiol-
pHAb the ﬂuorescence response to pH change was different than that
of free dye with half maximal response dropping to pH 6.0 (Fig. 3B).
Moreover, for thiol chemistry there still was some ﬂuorescence (~10%
of the maximum signal at pH-4.0) at pH ~ 8.0 which resulted in fold
increase in ﬂuorescence between pH 8.0 and pH 4.0 to be lower for
Trastuzumab-thiol-pHAb (10 fold) compared to that for free dyes or
Trastuzumab-amine-pHAb (~50 fold). A possible reason for unusual
response with thiol chemistry may be that pHAb dyes are restricted
into a very tiny space in the antibody hinge region causing local pH tond (B) Trastuzumab-thiol-pHAb. Responses of free amine reactive dye (pHAb-SE) and thiol
to buffer of desired pH in a 96 well plate and ﬂuorescence was measured using a 96 well
d deviation from triplicate readings were plotted.
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Cetuximab (not shown). Our results indicate that pHAb conjugated to
antibodies maintains its pH sensing properties and can be used for
internalization studies.
Moving forward, we decided to focus on four different antibody–
pHAb conjugates: Trastuzumab-amine-pHAb (DAR 3.5), Trastuzumab-
thiol-pHAb (DAR 3.4); Cetuximab-amine-pHAb (DAR 2.8) and
Cetuximab-THIOL-pHAb (DAR 2.8). Our decision was based on the
results from ELISA test and also on the fact that DARs between 2 and 4
have been reported (Vira et al., 2010) to be the best for labeling antibodies
and two FDA approved ADCs have a DAR of ~3.5 (Flygare et al., 2013).
3.2. pHAb conjugated antibodies enable real-time and homogeneous
internalization assay
To demonstrate the use of pHAb labeled antibodies for internaliza-
tion studies, we selected Trastuzumab-amine-pHAb (DAR 3.4) and
monitored its internalization in HER2 overexpressing SKBR3 cells
using confocal microscopy. 3.0 nM of Trastuzumab-amine-pHAb (DAR
3.4) was incubated with SKBR3 cells at 4 °C for 1 h to allow binding
but prevent any internalization. Cell media containing excess antibody
was replaced with phosphate buffer (pH 8.0) and imaged (Fig. 4A).
Since dye is not ﬂuorescent at pH 8.0, the cells are not visible. However
to make sure antibody is indeed bound to the receptors on the cellFig. 4. Internalization of Trastuzumab-amine-pHAbmonitored using confocal-microscopy. (A) S
antibodywas removed and replacedwith pH 8.0 buffer and imaged on a Nikon C2si confocal mi
the bufferwith citrate buffer (pH5.0) and cellswere imaged again to see theﬂuorescent antibod
and incubated at 37 °C for 18 h and imaged again. Punctate structures indicate internalized antib
the antibody.membrane, the buffer was replaced with citrate buffer (pH 5.0) to
make the dye ﬂuorescent and upon imaging (Fig. 4B) ﬂuorescence on
the cellmembranewas clearly visible. Bufferwas subsequently replaced
with DMEMmedia and cells were incubated at 37 °C for 24 h to initiate
internalization. Upon internalization, Trastuzumab-amine-pHAb
trafﬁcked into acidic vesicles like endosome and lysosomes and pHAb
dye became ﬂuorescent and was visible as punctate structures
(Fig. 4C). Binding and internalization is speciﬁc since no ﬂuorescence
was seen when MCF7 cells (HER2 negative) were used instead of
SKBR3 cells (Fig. 4D). To further ensure speciﬁcity, we incubated a
pHAb labeled nonspeciﬁc antibody, which should not bind to HER2
with SKBR3 cells, and saw no binding (result not shown).
Because ﬂuorescence is visible only when antibody is internalized,
we reasoned that it should be possible to monitor internalization in
real time without even removing the excess unbound antibody. To the
best of our knowledge, running internalization in real time in the pres-
ence of excess antibody hasn't been yet reported so far. Trastuzumab-
amine-pHAb (3.0 nM) was added to the cells and cells were imaged
every hour for 19 h (Fig. 5) showing the time dependent internalization
of Trastuzumab. Images in the ﬁrst 2 h show minimal ﬂuorescence
because Trastuzumab-amine-pHAb in the media and bound to the
membrane is not ﬂuorescent. Starting in the third hour, ﬂuorescence
is visible due to internalization and gradually increases over time. A
cropped and digitally enlarged image of cells captured at 17 h clearlyKBR3 cells were incubated for 1 h at 4 °Cwith 3.0 nMof Trastuzumab-amine-pHAb. Excess
croscope (Ex/Em: 561/580LP nm). (B) pH of themediawas changed to pH5.0 by replacing
y bound to the cell surface. (C) Citrate bufferwas removed and replacedwithDMEMmedia
ody. (D) No internalizationwas seenwhenHER2 negativeMCF7 cellswere incubatedwith
Fig. 5. Internalization kinetics of Trastuzumab-amine-pHAb monitored using confocal-microscopy. SKBR3 cells were incubated with 3.0 nM of Trastuzumab-amine-pHAb antibody and
images were collected every 1 h for 19 h on the Nikon C2si (Ex/Em: 561/580LP nm).
Fig. 6. Image of cells collected at 17 h in Fig. 5 is enlarged for clarity and to better highlight
the ﬂuorescent punctate structures.
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interesting observation was the differences between Figs. 4C and 6,
which should be due to differences in internalization in the absence
and presence of excess antibody respectively and may be worth
pursuing in later studies.3.3. Time and concentration dependent internalization of pHAb conjugated
antibodies in 96-well plate format
The ability to study real-time internalization kinetics of antibodies
will be very important in selecting antibodieswithmaximum therapeu-
tic efﬁcacy. However, due to limited throughput and qualitative data it is
not ideal as an antibody screening tool. We reasoned that due to the
dramatic increase in ﬂuorescence intensity of pHAb dyes at low pH,
homogeneous internalization assays could be done in a 96-well plate
format using a ﬂuorescent plate reader. To test the concept, 30 nM of
Trastuzumab and Cetuximab labeled with pHAb dye (using both thiol
and amine chemistries) were added at different time points to SKBR3
and A431 cells, respectively, and incubated at 37 °C. Mediawas replaced
with phosphate buffer (pH 7.2) and ﬂuorescence signal was measured
(Fig. 7). Internalization for all four antibodies could be detected within
1 h and ﬂuorescence signal increased over time and was not saturated
even after 24 h. Internalization was speciﬁc as no signal was seen
when these antibodies were incubated with MCF7 cells that do not
express either EGFR or HER2 receptors. Absolute ﬂuorescence signal at
24 h was lower for Trastuzumab-amine-pHAb antibodies compared to
Trastuzumab-thiol-pHAb and correlates with lower binding afﬁnity
observed using ELISA (Fig. 2). Lower ﬂuorescence signal upon internal-
ization was also observed for Cetuximab-amine-pHAb even though
Fig. 7. Amine and thiol conjugated Trastuzumab and Cetuximab (30 nM) was added to the SKBR3 and A431 cells respectively and incubated for various time points. Cell media was
replaced with PBS and plates read on a Tecan Inﬁnity M1000 plate reader at Ex/Em of 532 nm/560 nm. MCF7 cells were used as negative controls. Mean and standard deviation from
triplicate readings are plotted.
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thiol conjugated antibodies.
In addition to providing kinetic information, it is desirable to have a
sensitive internalization assay. A sensitive assay is important for identi-
fying internalizing antibodies during early antibody development phase
where the amount of antibody available is small and antibodymay have
low afﬁnities. To determine the sensitivity of the plate-based assay, a di-
lution series of Trastuzumab and Cetuximab labeled with pHAb dye
(using both thiol and amine chemistries) were added to SKBR3 and
A431 cells respectively and incubated at 37 °C for 24 h (Fig. 8). Assays
were sensitive and we were easily able to detect internalization of
0.3 nM (~30.0 pg/ml) of both Cetuximab and Trastuzumab. Sensitivity
obtained using a plate-based method was similar to that reported
using ﬂuorescent imaging and cell toxicity based methods (Pedersen
et al., 2010; Klussmanet al., 2004; Lewis Phillips et al., 2008). Noﬂuores-
cence was detected when Trastuzumab-pHAb dye was added to MCF7
cells containing no HER2 or EGFR receptors indicating the speciﬁcity
of internalization. It is also worth noting that absolute ﬂuorescence sig-
nal from internalization was lower for amine-conjugated antibodies.
3.4. Performance of antibody–pHAbdye conjugatewithout removing excess
free dye
Results so far, clearly show the utility of pHAb labeled antibodies for
internalization studies. However, step involving removal of free dye
after labeling is a major roadblock in cases where a large number of
samples is available and the amount of sample is limited. It is possible
to use 96 well dialysis setups that are commercially available but to
really simplify the labeling we wanted to know if removal of excessFig. 8. Internalization as a function of pHAb conjugated antibody concentration. (A) A concentrat
was added to SKBR3 cells (HER2positive) andMCF7 cells (HER2 negative) and incubated for 24h
Ex/Emof 532nm/560nm. (B) Internalizationwas alsomonitored for Cetuximab-amine-pHAb (D
negative). Mean and standard deviation of triplicate readings are plotted.free dye after conjugation is even necessary. We looked at the internal-
ization of Cetuximab labeled with pHAb dye with or without dialysis
step to remove excess dye (Fig. 9). Internalization proﬁle is similar for
dialyzed and un-dialyzed sample and is due to the fact that free excess
dye is not ﬂuorescent in the media and does not get internalized into
the cells indicating that dialysis step to remove excess dye is not neces-
sary. This approach may be difﬁcult to implement with thiol based
labeling chemistry since DTT used for reducing disulﬁde bonds will
still have to dialyzed otherwise it will interfere with the maleimide
chemistry. Replacing DTT with TCEP may be an option since TCEP
doesn't react readily with maleimide (Getz et al., 1999) but was not
tested in this report.3.5. Use of pHAb dye labeled secondary antibodies for screening antibodies
from cell media
Data presented so far have highlighted the advantages of usingpHAb
dyes for time and concentration dependent antibodies internalization
studies relevant during designing of therapeutic drug. These studies
used puriﬁed antibodies and hencewill have limited utility as screening
tool in early stages of antibody screening where antibodies are present
in the cell media. We recently reported an on-bead antibody labeling
and puriﬁcation method (Nath et al., 2015) that uses magnetic afﬁnity
beads to capture antibodies from the cellmedia followed by antibody la-
beling and puriﬁcation. However, the method still involves multiple
steps of washing and incubation. We therefore investigated whether
pHAb labeled secondary antibodies could be used instead of labeling
primary antibodies. The advantage for screening will be that pHAbion series of Trastuzumab-amine-pHAb (DAR3.5) and Trastuzumab-thiol-pHAb (DAR3.4)
. Cellmediawas replacedwith PBS and plates read onTecan InﬁnityM1000 plate reader at
AR2.8) andCetuximab-thiol-pHAb (DAR2.8)with A431 (EGFR positive) andMCF7 (EGFR
Fig. 9. Comparison of ﬂuorescence signal upon internalization obtained with and without
removing excess dyes after conjugation. Replicate samples of Cetuximabwere conjugated
with 20 M excess of pHAb dyes using amine chemistry and one sample was dialyzed to
remove excess dye whereas other sample was used as such. Two samples at 30 nM
were incubated with the A431 cells (EGFR positive) and MCF7 cells (EGFR negative) for
internalization and plates read. Average and standard deviation of 4 replicate samples
are plotted.
Table 2
List of commercially available anti EGFR antibodies used for internalization studies using
anti-mouse antibody conjugated with pHAb dyes using amine chemistry.
Company Catalog# Immunogen Antibody
Abcam 30 EGFR from A431 cells mIgG2B
231 Extracellular domain rIgG2A
8465 NA mIgG1
32198 Synthetic peptide mIgG1
124112 Peptide 424–605 (E. coli) mIgG2B
LS-Bio LS-C87999 EGFR from A431 cells mIgG2A
LS-C88001 EGFR from A431 cells mIgG1
LS-C888141 Extracellular domain mIgG1
Thermo MS268 EGFR from A431 cells mIgG2A
MS-269 EGFR from A431 cells mIgG1
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antibodies and then directly used for internalization.
25 nM of Goat anti-Human IgG labeled with pHAb dye using amine
chemistry (DAR = 2.5) was ﬁrst mixed with 1.0 nM and 10 nM of
Cetuximab and added to the A431 cells and read after 24 h incubation
(Fig. 10). Internalization of both 1.0 nM and 10.0 nM antibody concen-
trations were detected however absolute ﬂuorescent signal as well as
signal over background were lower compared to the method where
Cetuximab was directly labeled with pHAb dyes. We noticed that back-
ground was slightly higher with 25 nM of secondary antibody labeled
pHAb dye and ﬂuorescence signal was low. We attribute low ﬂuores-
cence signal to possible formation of large complexes, when multiple
secondary antibodies bind to the primary antibody (Harlow and Lane,
1998), resulting in inefﬁcient internalization. In spite of this limitation
the approach may be useful in primary screening method of antibodies
from cell media samples where antibody concentrations are typically in
the range of 10–50 μg/ml (~100–500 nM) and well within the
sensitivity of the assay.Fig. 10. Internalization of Cetuximab was performed using anti Human IgG labeled with
amine reactive pHAb dye. 25 nM of anti Human IgG-amine-pHAb was added to
Cetuximab at 0, 1.0 and 10.0 nM and added to A431 and MCF7 cells in a 96 well plate.
Cells were incubated for 24 h at 37 °C to allow internalization before reading
ﬂuorescence. Average and standard deviation of four replicate samples are plotted.To test the applicability of the assay for screening of antibodies, a
panel of commercial anti EGFR mouse monoclonal antibodies
(Table 2) was screened for internalization using anti-mouse conjugated
with pHAb dye using amine chemistry (Fig. 11). In parallel, cell based
ELISA was used to evaluate the binding of the antibodies to the EGFR
(Fig. 12). ELISA data indicates that antibodies raised using full length
EGFR from A431 are the best binders which is in agreement with
many published reports (Dreyer et al., 2010; Lim et al., 2011; Butler
et al., 1997) that antibodies screened against folded epitopes have a
better chance of binding a fully folded functional protein. However, of
the antibodies that bind to the EGFR, only four (Abcam 30, LifeBio —
LS-C87999 & C88141, and MS268) showed signiﬁcant internalization.
Our observation is in line with the reports that receptor-mediated
antibody internalization is epitope dependent (Pedersen et al., 2010;
Beers et al., 2010; Rudnick et al., 2011) and demonstrates the
importance of screening directly for internalization.
Real cell media samples were not available to us but the fact that 10
different samples could be easily tested in multiple replicates simulta-
neously, points to the utility of the method for screening purposes.
4. Discussion
Receptor-mediated antibody internalization is a key mechanism
driving the efﬁcacy of therapeutic antibodies but the current tools to
study internalization are cumbersome multistep processes and requireFig. 11. Fluorescence signal upon internalization obtained with commercially available
anti EGFR antibodies. A431 cells were incubated for 24 h with a mixture of 10 nM of
mouse anti EGFR monoclonal antibody and 25 nM of anti mouse antibody labeled with
pHAb dyes before reading the plate. Average and standard deviation of four replicate
samples are plotted.
Fig. 12. Cell based ELISA of commercial anti EGFR antibodies. Mean and standard deviation from triplicate readings are plotted. Data set was ﬁtted to a four parametric sigmoidal equation
using Graphpad.
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homogeneous assay for studying antibody internalization which, is
simple, robust and will be useful as a screening tool for selecting
antibodies with good internalization properties and also for under-
standing the mechanism of internalization for a speciﬁc antibody.
The internalization assay presented here relies on a pH sensitive
pHAb dye with low or no ﬂuorescence at pH N 7, which becomes highly
ﬂuorescent at the acidic pH typically present in early endosomes and
lysosomes. For the assay to be useful for antibody internalization,
pHAb dye was modiﬁed to have amine and thiol reactive groups for
labeling antibodies at lysines amino acids present at the antibody
surface or in the antibody hinge region where free thiol groups can be
generated by reducing disulﬁde binds between cysteine groups. In an
attempt to minimize the precipitation problem, pHAb dyes were
synthesized with two negatively charged sulfonate groups that make
the dye hydrophilic (Panchuk-Voloshina et al., 1999) and as a result
high DAR can be achievedwith various antibodieswithout precipitating
the antibodies (Table 1). However, stability of antibody–small molecule
conjugates is a complex phenomenon dependent on several factors
(Acchione et al., 2012; Shen et al., 2012) and it is possible that some
antibodies could still precipitate upon conjugation with pHAb dyes.
In addition to the stability of antibody–pHAb conjugate, preserving
antibody–antigen binding is also critical and was tested for various
antibody–pHAb conjugates (Fig. 1). Labeling antibodies using amine
chemistry is frequently used because there are around 80 lysine groups
in an antibody of which around 40 are accessible for modiﬁcation
(Flygare et al., 2013). When two antibodies were labeled with pHAb
dyes using amine chemistry,we sawa signiﬁcant impact on binding afﬁn-
ity in case of Trastuzumab but minimal impact on Cetuximab even at a
high DAR of 8.5. Loss of activity after labeling may be attributed to the
presence of modiﬁed lysines close to the antibody CDR region which
will have a detrimental impact on the antigen antibody binding and in
fact Trastuzumab has one lysine group in its CDR region, whereas
Cetuximab has none (Magdelaine-Beuzelin et al., 2007). Unlike amine
chemistry, thiol chemistry places the dye at the deﬁned position in the
hinge region away from the antibody CDR region and may be the reason
for minimal impact on the antibody binding afﬁnity seen with two anti-
bodies and reported in the literature (Hamblett et al., 2004). The relation-
ship between DAR, labeling chemistry and antibody activity is complex
and there are conﬂicting report in the literature with some
recommending a DAR of 2–4 as ideal (Vira et al., 2010), and in fact two
the FDA approvedADCs have aDARof ~3.5 (Flygare et al., 2013);whereas
other reports indicate no strict correlation betweenDAR and antibody ac-
tivity (Shrestha et al., 2012). Finally,we compared the pH response of free
pHAb dyes with pHAb dyes conjugated to antibodies and found a small
shift in pH response for pHAb dyes only when conjugated through thiol
groups. Fluorescent dyes are known to affect the ﬂuorescence yield
when in close proximity (Ogawa et al., 2010; Panchuk-Voloshina et al.,1999) and hence a shift for the pHAb dye is not surprising; however,
the pH response for the dye is still in the useful range to detect the pres-
ence of pHAb labeled antibodies in the acidic vesicles.
An enabling aspect of pHAb dye for internalization is that it will ﬂuo-
resce only when internalized into the acidic endosomal and lysosomal
vesicles. When cells overexpressing HER2 were incubated with
Trastuzumab-amine-pHAb, no ﬂuorescence was visible on the cell
membrane but imaging the cells at pH 5.0 showed the ﬂuorescence on
the outer membrane, conﬁrming that antibodies are indeed bound to
the receptors on the surface. After 24 h of incubation, highly ﬂuorescent
punctate structures indicative of internalization were clearly visible.
Under similar conditions, no internalization was seen with HER2
negative MCF7 cells indicating that binding and internalization were
speciﬁc. Confocal microscopy has been extensively used for antibody
internalization studies but most of these reports aremultistep endpoint
assays involving either stripping of membrane bound ﬂuorescent
antibodies using an acidic buffer or quenching of ﬂuorescence using
anti-ﬂuorophore antibodies (Casalini et al., 1993; Liao-Chan et al.,
2015). Moreover, most of these current assays involve incubating cells
with antibodies then removing the unbound antibody followed by in-
ternalization over a period. There are three problems with this ap-
proach: ﬁrst, this approach is not typical of in vivo scenario where
antibodies will be present around cancer cells for an extended period
of time; second, antibodies with higher off rates will dissociate from
the surface during incubation and will not be available for internaliza-
tion; third, newly synthesized receptors will remain unlabeled and
hence will not be visible upon internalization. For example, EGFR is
turned over with typical half-lives ranging from 8 to 24 h depending
on cell type and the level of EGFR expression (Sorkin and Duex, 2010).
In contrast, we reasoned that a dramatic increase in the ﬂuorescence
of pHAb dyes on internalization and relatively low background ﬂuores-
cence from membrane bound dyes would allow us to monitor the
internalization in real time without washing off the excess antibody.
Indeed, we were able to incubate SKBR3 cells in presence of 3 nM of
Trastuzumab-amine-pHAb (DAR 3.5) and image it continuously for
19 h. Minimal ﬂuorescence was seen at the initial time point and ﬂuo-
rescent intensity increased with time as evident by punctate structures.
Unlike the image in Fig. 3 where punctate structures were located
within the cells, the real time images show these structures to be around
the inside of the cell membranes as well as within the cells and may
indicate the dynamic process of antibody in early endosomes, late
endosomes and lysosomes. To the best of our knowledge, this is the
ﬁrst report of real-time monitoring of antibody internalization kinetics
and shows that additional information can be gleaned regarding the
mechanism of internalization.
Encouraged by the results from confocal microscopy, we expected
the assay be suitable in a 96-well plate format and that quantitative
data can be generated. Results obtained with Trastuzumab and
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within one hour of incubation and has not reached saturation even
after 24 h. Absolute ﬂuorescence signal from Trastuzumab-amine-
pHAb is lower compared to others and can be attributed to the loss of
antibody activity. The fact that the ﬂuorescent signal from internalization
is increasing even after 24 h may be result of several factors including:
(a) slow antibody internalization. For example, EGFR is known to rapidly
internalize in presence of EGF (Sorkin and Duex, 2010) whereas when
bound to antibody, receptor undergoes slow internalization (Pedersen
et al., 2010); (b) antibody–pHAb dye translocating into lysosomes
where antibody is degraded and pHAb dyes may be accumulating in the
lysosomes; (c) as internalization is done in the presence of excess anti-
body, new receptor may be getting expressed, labeled and internalized
leading to signal increase. Relatively few studies have looked at the
long-term antibody internalization (Pedersen et al., 2010; Gong and
Urlacher, 2015; Klussman et al., 2004; Lewis Phillips et al., 2008; Austin
et al., 2004) using tedious imaging based techniques, radioactivity mea-
surement or cell cytotoxicity. Our approach signiﬁcantly simpliﬁes the
process and should enable better understanding of the internalization
process at a higher throughput. Although not done here, it will be inter-
esting to see atwhat point the ﬂuorescence reaches saturation and the ul-
timate fate of the dye within the cell.
Previous experimentswere done at 30 nMbut bright ﬂuorescence of
thepHAbdye alloweddetection of internalization even at a very lowan-
tibody concentration (0.3 nM). To achieve maximum sensitivity in our
assays, we typically replace the media with a pH 7.5–8.0 phosphate
buffer, which reduces the small amount of pHAb ﬂuorescence present
at neutral pH and also reduces some quenching of signal from FBS con-
taining media. A sensitive assay will allow a wide array of antibodies
with different afﬁnities to be tested,whichwill typically be the case dur-
ing early antibody discovery phase. Moreover, in our case, the number
of receptors per cell is in the range of 1 to 2 million (Rusnak et al.,
2007), however, many cases will have a lower level of assays that will
require sensitive assays.
We have demonstrated the advantages of pHAb dyes in 96-well
plate based homogeneous assays for receptor-mediated antibody inter-
nalization; however, the need to label antibodieswith pHAb dyes can be
a challenge for wider applicability of this technology as screening tool.
One challenge during early antibody screening stage is the limited
amount of antibodies available for research. Hence dialysis steps in-
volved during labeling can be a major challenge. With amine conjuga-
tion chemistry, we are able to demonstrate that presence of excess
dye does not interfere with the internalization or with the assay sensi-
tivity. It can easily be envisioned that if a large panel of puriﬁed antibod-
ies is available in limited quantity, simply incubating with 5–20 molar
excess of amine reactive pHAb dye followed by internalization
experiment will allow the selection of promising lead candidates. This
approach is especially useful as puriﬁcation of antibodies at earlymono-
clonal screening stage using automated approaches becomes simpler. In
a complimentary approach, we also showed that a secondary antibody
labeled with pHAb dye can be used instead of labeling primary antibod-
ies. The use of secondary antibodies for internalization experiments has
been reported before (Klussman et al., 2004) but the effect of large pri-
mary and secondary antibody complexes on internalization needs to be
taken into account.
5. Conclusion
pHAb dyes are pH sensitive ﬂuorescent dyes that enable the study of
receptor-mediated antibody internalization. Internalization assays can
beperformed in a plate-based homogeneous format and allow endpoint
assays as well as real-time monitoring of internalization. We further
show that internalization can be monitored even at a very low amount
of antibody which is very important during the early monoclonal anti-
body development phase when the amount of sample is limited and
the antibody concentration in the samples is low. Plate-based sensitiveinternalization assays described here will enable screening of a large li-
brary of antibodies for their internalization properties andmay result in
more efﬁcient identiﬁcation of lead antibody candidates with superior
anti cancer efﬁcacy.
Note: During review process a paper similar to ours was published
andwill be useful to the readers Riedl, T., et al., High-throughput screen-
ing for internalizing antibodies by homogeneous ﬂuorescence imaging
of a pH-activated probe. J Biomol Screen, 2016. 21(1): p. 12–23.References
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